Background: Research indicates that a large proportion of patients using medication targeting obstructive lung disease have no history of spirometry testing. Objective: To investigate the use of spirometry when initiating pulmonary medication targeting obstructive lung disease and to explore possible patient characteristics associated with undergoing spirometry. Methods: Population-based cohort study. Three Danish National registers were linked enabling a retrieval of data on all primary and secondary healthcare services provided in the time period 2007e2010. Results: In 2008 a total of 40,969 patients were registered as first time users of pulmonary medication targeting obstructive lung disease. The mean age of the study cohort was 55.6 yrs (SD 18.7). Spirometry test had been performed in 20,262 (49.5%) of the study cohort in the period from 6 months before to 12 months after their first prescription. Just above one third of the cohort, 14,275 (34.8%), had undergone spirometry in the two-month period close to redemption of their first prescription. Women and patients in the oldest age categories were less likely to have spirometry performed. Conclusions: Many patients initiate medication targeting obstructive pulmonary disease without having airway obstruction confirmed through spirometry. Only one third of the study cohort had a spirometry performed when initiating medication and half had still not undergone spirometry after a year. There should be an increased focus on confirming airway obstruction when initiating medication. ª
Summary
Background: Research indicates that a large proportion of patients using medication targeting obstructive lung disease have no history of spirometry testing. Objective: To investigate the use of spirometry when initiating pulmonary medication targeting obstructive lung disease and to explore possible patient characteristics associated with undergoing spirometry. Methods: Population-based cohort study. Three Danish National registers were linked enabling a retrieval of data on all primary and secondary healthcare services provided in the time period 2007e2010. Results: In 2008 a total of 40,969 patients were registered as first time users of pulmonary medication targeting obstructive lung disease. The mean age of the study cohort was 55.6 yrs (SD 18.7). Spirometry test had been performed in 20,262 (49.5%) of the study cohort in the period from 6 months before to 12 months after their first prescription. Just above one third of the cohort, 14,275 (34.8%), had undergone spirometry in the two-month period close to redemption of their first prescription. Women and patients in the oldest age categories were less likely to have spirometry performed. Conclusions: Many patients initiate medication targeting obstructive pulmonary disease without having airway obstruction confirmed through spirometry. Only one third of the study cohort had a spirometry performed when initiating medication and half had still not undergone spirometry after a year. There should be an increased focus on confirming airway obstruction when initiating medication. ª 2012 Elsevier Ltd. All rights reserved.
Introduction
Spirometry is recommended as the gold standard for confirming obstructive lung disease and is a cornerstone in diagnosing the diseases asthma and chronic obstructive pulmonary disease (COPD). 1, 2 Initiating medication for obstructive lung disease without spirometry entails the risk that patients use this medication without evidence of airway obstruction. Neither clinical examination nor history taking can diagnose COPD adequately or distinguish it from asthma or other illnesses also giving respiratory symptoms.
3e5 Although medication relieves symptoms, reduces risk of exacerbations and improves quality of life, 6, 7 it is not without risk 8, 9 and spirometry should be performed to ensure correct diagnosis. 10 However, studies have shown that a large proportion of patients diagnosed with COPD or asthma have no history of spirometry testing.
11e14 Further, it has been indicated that many patients are prescribed medication for obstructive lung disease without a relevant diagnosis of COPD or asthma registered. 15, 16 We found no studies estimating the use of spirometry when initiating medication targeting obstructive lung disease. Some studies have shown gender differences in disease management 17 and age has also been identified as a factor influencing whether spirometry is performed. 18 The aim of this study was therefore to assess to what extent spirometry is conducted when initiating medication targeting obstructive lung disease, and to explore possible patient characteristics associated with undergoing spirometry.
Methods
This population-based cohort study links three national registers: the Danish National Prescription Register, the Danish National Patient Register and the Danish National Health Service Register. These registries cover the entire population of Denmark and contain information on all healthcare services provided. All Danish citizens are assigned a unique civil registration number (CPR), which enables accurate linkage between these registries. 19 Denmark has a tax-funded public healthcare system, providing free access to general practice and hospital care. More than 98% of Danish citizens are registered with a GP who act as a gatekeeper to the rest of the healthcare system by carrying out initial diagnostic investigations and referring patients to secondary care if necessary.
The Danish national registries
The Danish National Health Service Register contains information on all services provided in primary health care. Each registration includes the patients CPR, identification code for type of activity performed, e.g. spirometry, identification code for the primary healthcare clinic providing the health service and the week for reimbursement of the healthcare service. 20 The Danish National Patient Register records all hospital admissions, contacts to emergency departments and contacts to outpatient clinics. Each record includes the patients CPR, the date of admission, data on the hospital and diagnostic and procedure codes including spirometry. 21 The Danish National Prescription Register records all prescribed medications that are redeemed. Each prescription record includes the patient's CPR, identification code of the prescriber, date of purchase, the brand name, anatomical therapeutic chemical system code (ATC), dose unit and quantity. The daily dose and indication are not recorded in the database. 22 All medication targeting obstructive lung disease, defined as all medications within the ATC code R03, requires a prescription and registration is therefore complete. Medication with ATC code R03 include: Beta-2-agonists, anticholinergic drugs, inhaled corticosteroids, montelukast, theophylline, sodium cromoglycate, and omalizumab.
Sampling algorithm: identification of first time users of medication targeting obstructive lung disease
The Danish National Prescription Register was used to identify all adults who were first time users of medication targeting obstructive lung disease in 2008. Selection criteria were as follows: 1) All patients redeeming drugs with ATC code R03 in 2008 were identified, 2) patients under 18 years of age on 1 January 2008 were excluded, and 3) patients with records of previously redeemed prescriptions with ATC code R03 in the prescription database (1995e2007) were excluded. Sampling algorithm is demonstrated in Fig. 1 .The date the first prescription was redeemed was defined as the index date. Patients were defined as having repeated redemption of medication for obstructive lung disease if they redeemed more than one prescription of medication for obstructive lung disease (ATC R03) within a one-year interval and the interval between the two prescriptions exceeded 30 days. Number of therapies redeemed in the first year was assessed for each patient within the three main categories of R03 medication: Beta-2-agonists, anticholinergics and inhaled corticosteroids. Other medications within the ATC R03 category were rarely prescribed and were therefore excluded from analyses.
Spirometry
Records of spirometric procedures provided in the time period 2007e2010 were extracted from the Danish National Health Service Register and the Danish National Patient Register. Patients were categorized as having the spirometry performed in general practice, other primary care clinics or hospital setting. For each patient we assessed if spirometry was conducted in an 18-month period from 6 months before to 12 months after the index date. The shortest time interval between the index date and spirometry was extracted. Further, we assessed the proportion of patients who had spirometry performed in a two-month period from one month before to one month after the index date.
Statistics
Patient characteristics are reported using means and standard deviations (SD) to describe continuous variables and percentages (%) to describe categorical variables. Logistic regression models were used to calculate unadjusted and adjusted odds ratios (ORs) with 95% CIs for the associations between patient characteristics and spirometry in the 18-month period. The patient characteristics included were: gender, age, number of types of pulmonary medication initiated 12 months preceding the index date and if patients had redeemed prescriptions repeatedly. Pvalues < 0.05 were considered statistically significant. All statistical analyses were carried out using STATA 11 (STATACorp, College Station, TX, USA).
Ethics
This project is register-based and according to "The Act on Research Ethics Review of Health Research Projects in Denmark" only questionnaire surveys and medical database research projects involving human biological material are required to be notified to the research ethics committee. The research ethics committee has, therefore, not been contacted. The study was approved by the Danish Data Protection Agency, J.nr. 2011-41-5798.
Results

Cohort characteristics
A total of 40,969 patients >18 years were identified as first time users of medication targeting obstructive lung disease in 2008 (Fig. 1) . The mean age of the study cohort of first time users was 55.6 years (SD 18.7). There was a slight predominance of women (53.3% vs. 46.6%), and they were slightly younger (55.0 yrs (SD 19.1) vs. 56.3 yrs (SD 18.1)), ( Table 1) . The age distribution is shown in Fig. 2 . A total of 24,760 (60.4%) used only one type of pulmonary medication within the first year. Just about one third of the cohort 13,757 (33.6%) used two types of pulmonary medication. The remaining 2452 (6.0%) of the cohort used all three types of pulmonary medication within the first year. A total of 15,279 (37.3%) had redeemed medication prescriptions repeatedly, Table 1 .
Spirometry
The proportion of patients having undergone at least one spirometry in the period from 6 months before to 12 months after their first prescription is shown in Table 2 . A total of 20,262 (49.5%) of the study cohort had spirometry performed, whereas only 14,275 of the study cohort (34.8%) had a spirometry performed within the two-month period (data not shown). Among patients on monotherapy only 37.3% had spirometry performed, this increased to 65.7% among patients using two therapies and to 81.2% among patients using three therapies. In patients with repeated redemption of medication for obstructive lung disease, 69.9% had spirometry performed.
The time distribution from the index date to spirometry is shown in Fig. 3 . The figure also demonstrates in which setting the spirometry test was performed; the large majority were conducted in primary care. Table 3 shows crude and adjusted odds ratios for associations between spirometry testing and age, gender, number of pulmonary medication initiated and repeated redemption. Patients in age categories 28e47 years and above 68 years had statistically significantly lower chance of having spirometry performed in the 18-month period. For age category 78e87 years there was an adjusted odds ratio 0.51 (95% CI 0.46e0.56) compared with the youngest age category (18e27 years) and for age category þ88 years an adjusted OR of 0.15 (95% CI 0.12e0.18) for having A major strength is the population-based design reflecting an entire population's drug and health care utilization. Prescription data are complete; all redeemed prescriptions are registered, including all medication for obstructive lung disease, thereby capturing all first time users of this medication. Furthermore, our study comprises the entire healthcare system; all spirometry measurements from primary and secondary health care are assessed. The study may have some methodological limitations though; the Danish National Prescription Registry contains only redeemed prescriptions and it is therefore not possible to identify patients who do not redeem prescribed medication and they will be misclassified. However, we do not consider this misclassification to be a major problem as primary noncompliance is considered small. 23 The registry also has no data on the dose or indication for the drug, making it impossible for us to differentiate between different obstructive pulmonary diseases. As we aimed to assess whether spirometry is performed to confirm obstruction when medication targeting obstructive lung diseases is prescribed, we did not find diagnosis important for this study. However, although confirming obstruction through spirometry is mandatory in diagnosing COPD and recommended in asthma, repeated peak expiratory flow measurements (PEF) confirming variation of obstruction can be used as an alternative diagnostic strategy in young patients where COPD is unlikely. In Denmark all GP's have access to spirometry, making this preferred diagnostic strategy easy to perform. Although it cannot be excluded that PEF measurements to a minor extent might have substituted spirometry in the youngest age categories, PEF cannot be applied to the vast majority of the cohort and therefore does not significantly influence our findings.
Patient factors associated with spirometry
Identification of spirometric procedures depends on the comprehensiveness of the Danish National Health Service Register and the Danish National Patient Register. There are no studies assessing the consistency of coding of spirometric procedures in these two registries. An underreporting to these registers would lead to an underestimation of spirometry testing. Reporting of spirometry in primary health care is assumed to be high, because this is prerequisite for reimbursement. In secondary care coding is done routinely, it increases payment and is therefore also considered consistent. Although caution must be taken when interpreting data, we do not consider underreporting to be a significant problem. We were unable to find published studies assessing the utilization of spirometry in patients initiating medication targeting obstructive lung disease. The PLATINO study, by Montes et al., 16 estimated the prevalence of respiratory medication use and spirometry utilization among these medication users in five Latin American cities. Of the patients reporting use of any bronchodilator or corticosteroid in the previous 12 months, only 37.5% reported a history of spirometry testing. That study demonstrated a lower spirometry testing among medication users than the one found in our study. This difference could de due to study design and local differences. An interesting finding was that 70% of the patients receiving bronchodilators and/or corticosteroids had no airway obstruction when tested with spirometry; emphasizing the importance of confirmation of obstruction in patients using medication targeting obstructive lung disease. Joish et al. demonstrated that patients diagnosed with COPD were using medication before this diagnosis was registered and the median time from prescription to diagnosis was approximately one year. 15 These findings facilitate our hypothesis that patients use medication without a relevant diagnosis and spirometry testing is underused among medication users. Many studies have shown an underutilization of spirometry among patients with a diagnosis of asthma or COPD.
11e14,18,24 A Swedish study conducted by Arne et al. demonstrated that spirometry was only documented in 59% of the patients in connection with a diagnosis of COPD. 13 Our study confirms that this underutilization of spirometry is also present among patients initiating pulmonary medication targeting these illnesses.
Our study explored a possible association between spirometry and the patient's age and gender. We have not found any other studies comparing gender differences in spirometry utilization among pulmonary medication users. Three studies have compared gender differences in spirometry utilization among COPD patients; Watson et al. 17 found an underuse of spirometry testing among women (OR of 0.84, 95% C.I. 0.72e0.98) in concordance with Arne et al., 13 Han et al. 18 found the opposite. Although our study is not readily comparable with these studies we conclude that gender difference still persists. Patients in our study had a lower OR of having spirometry performed in age categories 28e47 years and in patients >68 years. The OR was lowest in age categories 78e87 years and above 88 years, in concordance with Han et al.'s 18 findings and it is noteworthy that both studies found a clear underuse in the oldest patients. There is no obvious explanation, but a similar finding has been seen in management of ischemic heart disease. 25 Correct diagnosis is essential in the oldest age groups, as increasing comorbidity increases the risk of misdiagnosis. We found that increasing number of therapies initiated and repeated redemption both significantly increased the chance of undergoing spirometry. This association is not surprising, as they could both be a proxy for disease severity. Only one third of the patients on monotherapy had spirometry performed, this increased to just two thirds in patients initiating two therapies, and even in patients initiating three therapies there is still one out of five who did not have spirometry performed. This study demonstrates that a high percentage of patients treated with medication targeting obstructive pulmonary diseases do not undergo spirometry. We found a clear underuse of spirometry in the oldest age categories and among women. Why prescribing is often done without confirmation of obstruction through spirometry testing remains unanswered, but efforts to increase spirometry utilization must be made.
